Antitumor activity of IL‐2/anti‐IL‐2 mAb immunocomplexes exerts synergism with that of N‐(2‐hydroxypropyl)methacrylamide copolymer‐bound doxorubicin conjugate due to its low immunosuppressive activity
Authors:
Open Access
- 16 December 2010
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 129 (8) , 2002-2012
Abstract
Interleukin (IL)‐2 has been approved for treatment of metastatic renal cancer and malignant melanoma. However, its unfavorable pharmacologic properties, severe side effects and the negative role of IL‐2 in maintaining T regulatory cells are severe drawbacks. It has been shown that immunocomplexes of IL‐2 and certain anti‐IL‐2 mAbs possess selective and high stimulatory activity in vivo. Here, we show that IL‐2/S4B6 mAb immunocomplexes expand not only CD122high subsets and newly activated CD8+ T cells but also natural killer T cells and γδ T cells. Further, we demonstrate that natural killer (NK) cells expanded by IL‐2/S4B6 mAb immunocomplexes in vivo have high cytolytic activity, which can be further increased by coadministration of IL‐12. We also demonstrate that IL‐2/S4B6 mAb immunocomplexes possess noticeable antitumor activity in two syngeneic mouse tumor models, namely BCL1 leukemia and B16F10 melanoma, but only if administered early in tumor progression. To effectively treat established tumors, we administered the tumor‐bearing mice first with N‐(2‐hydroxypropyl)methacrylamide copolymer‐bound doxorubicin conjugate, and subsequently with IL‐2/S4B6 mAb immunocomplexes alone or with IL‐12 to induce an efficient antitumor immune response. Importantly, we show that the conjugate has significantly lower immunosuppressive activity than free doxorubicin when using dosage with comparable antitumor activity, thus eliminating the majority of tumor cells while leaving the immune system mostly unimpaired for stimulation with IL‐2/S4B6 mAb immunocomplexes. Indeed, we demonstrate that the conjugate and IL‐2/S4B6 mAb immunocomplexes together have synergistic antitumor activity.Keywords
This publication has 34 references indexed in Scilit:
- In Vivo Expansion of Activated Naive CD8+ T Cells and NK Cells Driven by Complexes of IL-2 and Anti-IL-2 Monoclonal Antibody As Novel Approach of Cancer ImmunotherapyThe Journal of Immunology, 2009
- In vivo expansion of T reg cells with IL-2–mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppressionJournal of Experimental Medicine, 2009
- Adjuvants targeting innate and adaptive immunity synergize to enhance tumor immunotherapyProceedings of the National Academy of Sciences, 2008
- Rapid generation of a functional NK-cell compartmentBlood, 2007
- Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapyNature Medicine, 2007
- The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine designNature Reviews Immunology, 2006
- Converting IL-15 to a superagonist by binding to soluble IL-15RαProceedings of the National Academy of Sciences, 2006
- Induction of Systemic Antitumour Resistance with Targeted PolymersScandinavian Journal of Immunology, 2005
- Acquired and specific immunological mechanisms co-responsible for efficacy of polymer-bound drugsJournal of Controlled Release, 2002
- lnterleukin-2: Solid-Tumor TherapyOncology, 1994